A majority of countries report having policies to also optimise the clinical use of plasma derivatives, with a small number of countries having national prioritisation strategies to ensure supply to those patient groups who are highly dependent on treatment with these products.
Un reducido número de países dispone además de estrategias nacionales de priorización para garantizar el suministro a los grupos de pacientes altamente dependientes de tratamientos con esos productos.